Pre-treatment cytogenetic and molecular entities shown to predict disease outcome in multivariable analysis studies conducted in younger adults.
| . | Cytogenetic/molecular abnormality . | Comments . |
|---|---|---|
| Favorable | t(15;17)(q22;q12~21)/PML-RARA t(8;21)(q22;q22)/RUNX1-RUNX1T1 inv(16)(p13q22)/t(16;16)(p13;q22)/CBFB-MYH11 | Irrespective of additional cytogenetic abnormalities |
| NPM1 mutant/FLT3-ITD−, WT1 wild type CEBPA mutant (biallelic, FLT3-ITD−) | ||
| Intermediate | Entities not classified as favorable or adverse | |
| Adverse | abn(3q) [excluding t(3;5)(q21~25;q31~35)], inv(3)(q21q26)/t(3;3)(q21;q26)/EVI-1 expression add(5q), del(5q), −5, −7, add(7q), t(6;11)(q27;q23), t(10;11)(p11~13;q23), t(9;22)(q34;q11), −17, abn(17p) with other changes Complex (>3 unrelated abnormalities) | Excluding cases with favorable karyotype |
| FLT3-ITD | In absence of favorable karyotype. Particularly poor prognosis with high level FLT3-ITD mutant ratio or if FLT3-ITD accompanied by WT1 mutation | |
| MLL-PTD |
| . | Cytogenetic/molecular abnormality . | Comments . |
|---|---|---|
| Favorable | t(15;17)(q22;q12~21)/PML-RARA t(8;21)(q22;q22)/RUNX1-RUNX1T1 inv(16)(p13q22)/t(16;16)(p13;q22)/CBFB-MYH11 | Irrespective of additional cytogenetic abnormalities |
| NPM1 mutant/FLT3-ITD−, WT1 wild type CEBPA mutant (biallelic, FLT3-ITD−) | ||
| Intermediate | Entities not classified as favorable or adverse | |
| Adverse | abn(3q) [excluding t(3;5)(q21~25;q31~35)], inv(3)(q21q26)/t(3;3)(q21;q26)/EVI-1 expression add(5q), del(5q), −5, −7, add(7q), t(6;11)(q27;q23), t(10;11)(p11~13;q23), t(9;22)(q34;q11), −17, abn(17p) with other changes Complex (>3 unrelated abnormalities) | Excluding cases with favorable karyotype |
| FLT3-ITD | In absence of favorable karyotype. Particularly poor prognosis with high level FLT3-ITD mutant ratio or if FLT3-ITD accompanied by WT1 mutation | |
| MLL-PTD |